Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20250150 | 0.89 | ELOVL1 (0.73) | ELOVL1ALDH1A1TRPA1MAPTANO1 | |
| SCHEMBL20249956 | 0.88 | ELOVL1 (0.71) | ELOVL1ALDH1A1TRPA1MAPTANO1 | |
| SCHEMBL20249761 | 0.86 | ELOVL1 (0.79) | ELOVL1ALDH1A1TRPA1MAPTABL1 | |
| SCHEMBL20249913 | 0.86 | ELOVL1 (0.68) | ELOVL1ALDH1A1TRPA1MAPTANO1 | |
| SCHEMBL20250641 | 0.85 | ELOVL1 (0.73) | ELOVL1ALDH1A1TRPA1MAPTABL1 | |
| SCHEMBL20250112 | 0.85 | ELOVL1 (0.73) | ELOVL1ALDH1A1TRPA1MAPTABL1 | |
| SCHEMBL20242258 | 0.85 | ELOVL1 (0.70) | ELOVL1MAPTABL1CACNA1GCACNA1H | |
| SCHEMBL20249935 | 0.85 | ELOVL1 (0.84) | ELOVL1ALDH1A1TRPA1MAPTCACNA1G | |
| SCHEMBL20250027 | 0.84 | ELOVL1 (0.72) | ELOVL1ALDH1A1TRPA1MAPTABL1 | |
| SCHEMBL20249783 | 0.84 | ELOVL1 (0.82) | ELOVL1ALDH1A1TRPA1MAPTABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | claimed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | ELOVL1 39/4885ALDH1A1 69/4885TRPA1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.